

Correction: Updated Information on OPPS Reimbursement

We have identified an error in the previously published table regarding the coding for mechanical scalp cooling. The table has now been updated, and the corrected figures are marked in italic text.

Category I CPT codes for mechanical scalp cooling and brief description	АРС	OPPS CY 2026 Rates	MPFS CY 2026 Rates	Example: MPFS rate for 6 treatments*
97007 - Initial cap fitting and patient education	1516	\$1,450.50	\$1,883.43 per patient, per treatment cycle	\$1,883.43
97008 - Pre-cooling period	N/A	N/A	\$55.80 per treatment	\$334.80
97009 - Post-infusion cooling, per each 30 minute period	N/A	N/A	\$32.31 per unit, per treatment	\$775.44

^{*}Average number of treatments per patient is six. Average post infusion cooling time is up to 120 minutes.

Learn more about Paxman's Scalp Cooling System: www.paxmanscalpcooling.com

Contacts

Richard Paxman, CEO Tel: +44 7968 020641

Email: richard@paxmanscalpcooling.com

www.paxman.se



About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. In 2025, PAXMAN AB acquired Dignitana, merging to form a stronger united company.

Today, PAXMAN's portfolio includes both the Paxman and DigniCap systems with several thousand installations in hospitals, clinics and treatment centres worldwide, reaffirming PAXMAN as the leading global supplier of Scalp Cooling technology.

PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden). Subsidiaries of the PAXMAN Group are Paxman Coolers Limited (Huddersfield UK), Paxman Inc. (Houston, Texas US), Paxman Canada (Toronto, Ontario CA), Dignitana AB (Lund, Sweden), Dignitana Inc. (Dallas, TX US), and Dignitana S.r.I. (Milan, IT).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser.

Attachments

Updated Information on OPPS Reimbursement